8-K/A: CareDx Reports Strong 2025, Appoints New CFO/COO

CareDx, Inc. announced robust financial results for Q4 and full year 2025, including 14% full-year revenue growth, alongside a key executive appointment and 2026 financial guidance.

Summary

• Full Year 2025 Total Revenue reached $380 million, marking a 14% increase year-over-year.
• Fourth Quarter 2025 Total Revenue was $108 million, a 25% increase compared to the prior year's quarter.
• The company reported a GAAP net loss of $21 million for the full year 2025 and $4 million for the fourth quarter of 2025.
• Adjusted EBITDA for the full year 2025 was $32 million, an increase from $28 million in 2024, while Q4 2025 Adjusted EBITDA was $7 million, down from $10 million in Q4 2024.
• CareDx expects full year 2026 revenue to be in the range of $420 million to $444 million, and adjusted EBITDA between $30 million and $45 million.
• Keith Kennedy has been appointed as the company's Chief Financial Officer and Chief Operating Officer, effective February 26, 2026.
• Nathan Smith resigned from his position as Chief Financial Officer for personal reasons, effective February 25, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed filing. While revenue growth is strong and strategic initiatives are progressing, the GAAP net loss and a decline in Q4 adjusted EBITDA, even with explanations, temper the overall positive sentiment.

Positives

• Full Year 2025 Total Revenue increased 14% year-over-year to $380 million.
• Q4 2025 Total Revenue increased 25% year-over-year to $108 million.
• Testing services revenue grew 23% in Q4 2025 to $78 million and 10% for the full year 2025 to $275 million.
• Patient and digital solutions revenue grew 47% in Q4 2025 to $16.8 million and 31% for the full year 2025 to $57 million.
• Product revenue grew 17% in Q4 2025 to $13.3 million and 19% for the full year 2025 to $48 million.
• Cash flow from operations was $21.4 million in Q4 2025 and $42 million for the full year 2025.
• Share repurchases totaled $12 million (773,000 shares at an average price of $15.79 per share) in Q4 2025 and $88 million (5.8 million shares at an average price of $15.16 per share) for the full year 2025.
• Cash, cash equivalents, and marketable securities were approximately $200 million as of December 31, 2025.
• Full Year 2025 Adjusted EBITDA increased to $32 million from $28 million in 2024.
• Published the third SHORE registry manuscript, reinforcing clinical evidence for HeartCare.
• Advanced Epic Aura integrations, with seven transplant centers live and approximately twenty implementations underway.
• Launched ImmuneScape through a strategic collaboration with 10x Genomics, establishing a multiomics discovery platform.
• Announced pivotal validation data for AlloHeme, advancing expansion into cell therapy and hematologic malignancies.

Negatives

• GAAP net loss of $4 million in Q4 2025, compared to GAAP net income of $88 million in Q4 2024.
• GAAP net loss of $21 million for the full year 2025, compared to GAAP net income of $53 million in 2024 (which included a $96 million reversal of a litigation accrual).
• Adjusted EBITDA of $7 million in Q4 2025, compared to $10 million in Q4 2024, which includes approximately $7 million of operating expenses for compensation in lieu of equity grants for non-executives.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors.
• Global economic and marketplace uncertainties could adversely impact the company's actual results, performance, or achievements.
• Other risks discussed in the company's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, could affect future performance.

Future Outlook

CareDx expects full year 2026 revenue to be in the range of $420 million to $444 million, which includes an estimated 6-month impact of the Medicare LCD of approximately $7.5 million. The company also anticipates full year 2026 adjusted EBITDA to be in the range of $30 million to $45 million.

Management Comments

• "We delivered a strong finish to 2025, reflecting disciplined execution across the business and continued momentum in our core testing services, patient and digital solutions, and lab products."
• "As we enter 2026, we believe we are well positioned to build on this momentum and continue delivering meaningful value for transplant patients, clinicians, and shareholders."

Industry Context

StockSavvy.ai notes that CareDx operates in the specialized and growing precision medicine sector for transplant patients, a market driven by the increasing demand for non-invasive diagnostics and personalized care. The company's focus on multiomics discovery platforms like ImmuneScape and expansion into cell therapy with AlloHeme indicates a strategic move to broaden its market reach and maintain a competitive edge against other diagnostic firms by leveraging advanced genomic technologies. The Epic Aura integrations suggest a push towards better clinical workflow integration, a key factor for adoption in healthcare settings.

Comparison to Industry Standards

• CareDx's 14% year-over-year revenue growth for 2025 is robust, potentially outpacing some broader diagnostic market growth rates, which typically range from mid-single digits to low double-digits for established players.
• The expansion into cell therapy and hematologic malignancies with AlloHeme positions CareDx to compete with specialized diagnostics companies like Natera (Prospera) and Eurofins (Transplant Genomics), which also offer molecular transplant diagnostics, by diversifying its portfolio beyond solid organ transplantation.
• The strategic collaboration with 10x Genomics for ImmuneScape aligns with industry trends towards multiomics approaches, similar to efforts by companies like Illumina or Thermo Fisher Scientific in broader genomic research, aiming to enhance diagnostic precision.

Management Changes

Corporate Governance

Legal Proceedings

• The full year 2024 GAAP net income included a $96 million reversal of a litigation accrual associated with damages related to the alleged infringement of patent '544 accrued in 2023. No new legal proceedings are mentioned in this filing.

Related Party Transactions

• There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and Mr. Kennedy.

Stakeholder Impact

• Shareholders: Positive impact from share repurchases ($88 million in 2025), strong revenue growth, and positive cash flow from operations. Mixed impact from GAAP net loss but positive non-GAAP net income and adjusted EBITDA growth. Executive changes aim for continued strategic execution.
• Employees: Changes in executive leadership (CFO/COO appointment, CFO resignation). Compensation in lieu of equity grants for non-executives in Q4 2025.
• Customers (Transplant Patients/Clinicians): Continued development and commercialization of precision medicine solutions (HeartCare, AlloHeme), advancements in workflow integration (Epic Aura), and new discovery platforms (ImmuneScape) aim to improve patient outcomes and clinician efficiency.
• Creditors: Strong cash position ($200 million) and positive cash flow from operations indicate financial stability.

Next Steps

• Filing of the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC on February 25, 2026.
• Filing of the Release Agreement with Nathan Smith as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2026.
• Continued building on momentum in core testing services, patient and digital solutions, and lab products in 2026.
• Further Epic Aura implementations (approximately twenty underway).

Key Dates

Recommendation

While CareDx demonstrated strong revenue growth and positive operational momentum in 2025, the GAAP net loss for both Q4 and the full year, alongside a decline in Q4 adjusted EBITDA (even with an explanation), presents a mixed financial picture. The 2026 guidance is positive, but the estimated impact of the Medicare LCD introduces some uncertainty. The executive changes appear well-managed, with an internal promotion to CFO/COO. For a seasoned investor, the company shows promise in a growing market, but the GAAP profitability concerns and the Medicare LCD impact warrant a 'hold' position to observe how the company navigates these factors in 2026.

Keywords

CareDx, CDNA, transplant diagnostics, precision medicine, financial results, Q4 2025, full year 2025, 2026 guidance, CFO appointment, COO appointment, executive change, SEC filing, 8-K/A, HeartCare, AlloHeme, Epic Aura, ImmuneScape, molecular testing, organ health, biotechnology, healthcare solutions